Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, parallel-group, placebo-controlled, active-controlled study of the efficacy and safety of sustained-release quetiapine (Seqoquel) compared with placebo in the treatment of generalized anxiety disorder

Trial Profile

A multicenter, randomized, double-blind, parallel-group, placebo-controlled, active-controlled study of the efficacy and safety of sustained-release quetiapine (Seqoquel) compared with placebo in the treatment of generalized anxiety disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2011

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Escitalopram (Primary) ; Quetiapine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms GOLD
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Dec 2011 Results from a pooled analysis published in the Human Psychopharmacology: Clinical and Experimental.
    • 28 Jun 2009 Planned pooled analysis of data from the GOLD, SILVER and TITANIUM trials presented at the 9th World Congress of Biological Psychiatry.
    • 19 May 2009 Planned pooled analysis of data from the GOLD, SILVER and TITANIUM and PLATINUM trials presented at the 162nd Annual Meeting of the American Psychiatric Association (APA 2009).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top